


Amendments to the Claims

Please cancel claims 13, 15-17 and 20. Please amend claims 1-10, 12, 14, 18 and 19. Please add new claims 21-25. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A compound selected from the ~~specific~~ group of compounds that ~~comprises or consists~~ consisting of compounds of formula (I) ~~[[or]]~~ and compounds of formula (II):



wherein:

R1 and R2 are joined to form a ring system; or

R1 is H; and

R2 is 2-pyridin-4-yl-ethyl; 3-chloro-benzyl; benzo[1,3]dioxol-4-ylmethyl; 4-sulfonamide-benzyl; benzyl; thiophen-2-ylmethyl; 1-phenyl-ethyl; 4-(4-amino-benzoylamino)-phenyl; 4-methoxy-benzyl; 1-hydroxymethyl-2-methyl-propyl; 2-Pyridin-3-yl-ethyl; 4-phenoxy-phenyl;; 4-fluoro-phenyl; 4-[ethyl-(2-hydroxy-ethyl)-amino]-phenyl; C1-C6 optionally substituted alkyl, ~~eg including ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3-hydroxy-propyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2-hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2-morpholin-4-yl-ethyl, furan-2-yl-methyl;~~ C3-C6 optionally substituted cycloalkyl ~~eg including cyclohexane;~~ 5 to 7 membered optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen, ~~preferably piperazine ring, [1,4]diazepane or a pyrrolidine ring;~~ R2 is optionally linked to the scaffold by a linker which includes 1 to 3 carbon atoms;

R3 is benzofuran-2-yl; naphthalen-2-yl; 3-4-methoxy-phenyl; 4-thiomethyl-phenyl; benzothiophen-2-yl; 4-pyridyl; 4-methoxy-phenyl; quinolin-3-yl; benzo[1,3]dioxol-5-yl; 4-hydroxy-phenyl; 4-trifluoromethoxy-phenyl; 3-chloro-4-pyridyl; 3-4-5-methoxy-phenyl; 5-acetyl-thiophen-2-yl; 3-trifluoromethoxy-phenyl; 4-hydroxymethyl-phenyl; N-(4-Methoxy-phenyl)-benzamide-4-yl; 3-fluoro-4-chloro-phenyl; N-(2-Hydroxy-ethyl)-4-benzamide-4-yl; 3-hydroxy-phenyl; 3-acetylamino-phenyl; quinolin-7-yl; 2-methoxy-5-isopropyl-phenyl; 3-hydroxymethyl-phenyl; 3-pyridyl; hex-1-enyl; 4-cyano-phenyl; thiophen-3-yl; 3-nitro-phenyl; 3-chloro-phenyl; 2-methoxy-phenyl; 4-isopropyl-phenyl;

R4 and R5 are joined to form a ring system; or

R4 is H or methyl; and

R5 is 3-hydroxy-phenyl; 3-hydroxybenzoyl; 4-bromo-benzyl; 4-methoxybenzyl; 2,5-hydroxybenzyl; 3-hydroxy-4-methoxy-benzyl; 3-chloro-benzyl; 3-fluoro-4-chloro-benzyl; 3-amino-benzyl; 3-trifluoromethoxy-benzyl; 4-hydroxy-benzyl; 4-amino-benzyl; 1H-Indol-6-yl; 3-hydroxy-benzyl; naphthalen-2-yl-methyl; benzo[1,3]dioxol-4-ylmethyl; 3,4-fluoro-benzyl; 3,4-chloro-benzyl; furan-3-yl-methyl; 4-methoxy-phenyl; 4-chloro-benzyl; 3-nitro-phenyl; 3,4-methoxy-phenyl; 3-bromo-phenyl; 4-chloro-phenyl; phenyl; 3-chloro-phenyl; 2-naphtyl; pyridin-3-yl-methyl; pyridin-4-yl-methyl; quinolin-3-yl-methyl; 4-isopropyl-phenyl; 4-chloro-benzyl; 3,4-methoxy-benzyl; 3-fluoro-4-chloro-phenyl; 4-trifluoromethoxy-phenyl; 4-cyano-phenyl; 4-methoxy benzyl, 4-methoxy-3-hydroxy benzyl; pyridin-4-yl-ethyl; piperidine-1-carboxylic acid benzyl ester 3-yl-methyl; cyclohexane-methyl; 4-chlorobenzoyl; pyrrolidine-2-yl-methyl; C1-C6 optionally substituted alkyl, ~~eg including ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3-hydroxy-propyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2-hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2-morpholin-4-yl-ethyl, furan-2-yl-methyl;~~ C5-C7 optionally substituted cycloalkyl ~~eg including cyclohexane;~~ 5 to 7 membered optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen, ~~eg including a piperazine ring, [1,4]diazepane or a pyrrolidine ring;~~ and R5 is optionally linked to the scaffold by a linker which includes 1 to 3 carbon atoms; and

R6 is 3-carbamoyl-phenyl; 4-hydroxy-phenyl; 4-amino-phenyl; 3-amino-phenyl; phenyl; 1H-Indol-5-yl; 4-pyridyl; 3-hydroxy-phenyl; Benzo[1,3]dioxol-5-yl; 3-(2-Hydroxy-ethylcarbamoyl)-phenyl; 3-hydroxymethyl-phenyl; 3-acetylamino-phenyl; 4-hydroxymethyl-phenyl; 3-(2-dimethylamino-ethylcarbamoyl)-phenyl; thiophene-3-yl; 3-pyridyl; 3,4-methoxy-phenyl; 6-Bromo-1-carboxylic acid tert-butyl ester-indol-2-yl; 3-(2-hydroxy-ethylcarbamoyl)-phenyl; 3-Methanesulfonylamino-phenyl; 3-trifluoromethoxy-phenyl; 4-hydroxymethyl-phenyl;

4-methanesulfonyl-phenyl; quinolin-3-yl; 5-methoxy-pyridin-3-yl; 4-carbamoyl-phenyl; 4-acetylamino-phenyl; 4-Methylcarbamoyl-phenyl; 4-(2-Hydroxy-ethylcarbamoyl)-phenyl; quinolin-4-yl; quinolin-5-yl; isoquinolin-4-yl; 1H-pyrazol-4-yl; 3-chloro-pyridin-4-yl; 3-methoxy-pyridin-5-yl; 4-methoxy-pyridin-5-yl; or 2-methyl-pyridin-4-yl; benzothiophene-2-yl; 3-chloro-pyridine-4-yl; 1H-pyrazol-3-yl; isoquinolin-3-yl; 4-carbamoyl-phenyl; 4-carbamoyl-phenyl; 3-(2-Hydroxy-ethylcarbamoyl)-phenyl.

2. (Currently amended) [[A]] The compound according to claim 1, wherein R1 and R2 form a 5 to 7 membered ring optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen.

3. (Currently amended) [[A]] The compound according to claim 2 wherein the ring is selected from the group consisting of 2-(2-hydroxy-ethyl)-piperidin-1-yl or 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-methyl-piperazin-1-yl; 4-pyridin-4-yl-piperazin-1-yl; 4-(2-dimethylamino-ethyl)-piperazin-1-yl; 4-(2-diethylamino-ethyl)-piperazin-1-yl; morpholin-4-yl; 4-(2-cyano-phenyl)-piperazin-1-yl; 4-methyl-[1,4]diazepan-1-yl; N-(2-dimethylamino-ethyl)-N-methyl-; 4-(3,4-dimethoxy-phenyl)-piperazin-1-yl; 4-pyridin-2-yl-piperazin-1-yl; 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-(furan-3-carbonyl)-piperazin-1-yl; 4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl[[; or]] and 2-(2-hydroxy-ethyl)-pyrrolidin-1-yl.

4. (Currently amended) [[A]] The compound according to claim 1 wherein R4 and R5 form a 5 to 7 membered ring optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen.

5. (Currently amended) [[A]] The compound according to claim 4 wherein the ring is selected from the group consisting of 2-(2-hydroxy-ethyl)-piperidin-1-yl or 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-methyl-piperazin-1-yl; 4-pyridin-4-yl-piperazin-1-yl; 4-(2-dimethylamino-ethyl)-piperazin-1-yl; 4-(2-diethylamino-ethyl)-piperazin-1-yl; morpholin-4-yl; 4-(2-cyano-phenyl)-piperazin-1-yl; 4-methyl-[1,4]diazepan-1-yl; N-(2-dimethylamino-ethyl)-N-methyl-; 4-(3,4-dimethoxy-phenyl)-piperazin-1-yl; 4-pyridin-2-yl-piperazin-1-yl; 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-(furan-3-carbonyl)-piperazin-1-yl; 4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl[[; or]] and 2-(2-hydroxy-ethyl)-pyrrolidin-1-yl.

6. (Currently amended) ~~[[A]]~~ The compound according to claim 1, wherein:
R1 is hydrogen;
R2 is 2-pyridin-4-yl-ethyl; thiophen-2-ylmethyl; 4-sulfonamide-benzyl; or 3-chloro-benzyl;
R3 is benzothiophen-2-yl; naphthalen-2-yl; 3-4-methoxy-phenyl; or 4-pyridyl;
R4 is hydrogen;
R5 is 3-hydroxy-benzyl; 4-chloro-benzyl; naphthalen-2-yl-methyl;
benzo[1,3]dioxol-4-ylmethyl; 3,4-fluoro-benzyl; 3,4-chloro-benzyl; or furan-3-yl-methyl;
and
R6 is 3-carbamoyl-phenyl; 4-hydroxy-phenyl; or 4-pyridyl.
7. (Currently amended) ~~[[A]]~~ The compound according to claim 1 that is selected from the group of compounds named in Table A or Table B.
8. (Currently amended) A method for making a compound according to claim 1 ~~any one of claims 1 to 7~~, which method comprises at least one step or a series of consecutive steps from the scheme defined herein.
9. (Currently amended) A group of two or more compounds comprising two or more compounds of claim 1 ~~or consisting of a set of structurally related compounds having a core chemical structure (scaffold) of a general formula selected from the group consisting of formula I or II.~~
10. (Currently amended) ~~[[A]]~~ The group of two or more compounds according to claim 9 ~~which comprises compounds according to any one of claims 1 to 7, and said group has wherein~~ all or substantially all of the permitted substitutions of formula (I) and formula (II) are represented by compounds in said group therein.
11. (Original) A method for making a group of compounds according to claim 10, which method comprises at least one step or a series of consecutive steps from the scheme defined herein.

12. (Currently amended) An assay comprising a ~~group of compounds according to claim 9, or one or more compounds~~ compound according to claim 1 ~~any one of claims 1 to 7.~~

13. (Canceled)

14. (Currently amended) A pharmaceutical composition that comprises a compound according to claim 1 and a pharmaceutically acceptable carrier ~~any one of claims 1 to 7 or a compound identified in an assay according to claim 12.~~

15-17. (Canceled)

18. (Currently amended) A method of treatment of a condition characterised by abnormal kinase activity that comprises administering a pharmaceutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 7.~~

19. (Currently amended) ~~[[A]]~~ The method of treatment according to claim 18 wherein the condition is selected from cardiovascular disease (~~coronary vasospasm, hypertensive disease, arteriosclerosis~~), stroke, cancer, erectile dysfunction, asthma, osteoporosis~~[[.]]~~, glaucoma and AIDS.

20. (Canceled)

21. (New) The compound according to claim 1, wherein R2 is a C1-C6 optionally substituted alkyl, C3-C6 optionally substituted cycloalkyl, or 5 to 7 membered optionally substituted ring containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein

said C1-C6 optionally substituted alkyl is selected from the group consisting of ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3-hydroxy-propyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2-hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2-morpholin-4-yl-ethyl, and furan-2-yl-methyl;

said C3-C6 optionally substituted cycloalkyl is optionally substituted cyclohexyl;
and

said 5 to 7 membered optionally substituted ring containing 1 to 3 heteroatoms selected from nitrogen and oxygen is optionally substituted piperazinyl, optionally substituted [1,4]diazepanyl or optionally substituted pyrrolidinyl.

22. (New) The compound according to claim 1, wherein R2 is a C1-C6 optionally substituted alkyl, C5-C7 optionally substituted cycloalkyl, or 5 to 7 membered optionally substituted ring containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein

said C1-C6 optionally substituted alkyl is selected from the group consisting of ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3-hydroxy-propyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2-hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2-morpholin-4-yl-ethyl, and furan-2-yl-methyl;

said C5-C7 optionally substituted cycloalkyl is optionally substituted cyclohexyl; and

said 5 to 7 membered optionally substituted ring containing 1 to 3 heteroatoms selected from nitrogen and oxygen is optionally substituted piperazinyl, optionally substituted [1,4]diazepanyl or optionally substituted pyrrolidinyl.

23. (New) The method of claim 19 wherein the condition is cardiovascular disease and said cardiovascular disease is selected from the group consisting of coronary vasospasm, hypertensive disease and arteriosclerosis.
24. (New) A pharmaceutical composition that comprises a compound according to claim 6 and a pharmaceutically acceptable carrier.
25. (New) A pharmaceutical composition that comprises a compound according to claim 7 and a pharmaceutically acceptable carrier.